In addition, in non-small cell lung cancer, a large number of clinical trial data support that the combination of PD-1/PD-L1 inhibitors and radiotherapy improves overall survival (OS) and progression-free survival (PFS), and significantly improves patients’ quality of life. This evidence concerns the gene CD274 and non-small cell lung carcinoma.